Mesoblast (NASDAQ:MESO) Shares Gap Up – Should You Buy?

Shares of Mesoblast Limited (NASDAQ:MESO) gapped up prior to trading on Tuesday . The stock had previously closed at $10.84, but opened at $11.12. Mesoblast shares last traded at $11.29, with a volume of 37,431 shares changing hands.

Analyst Ratings Changes

Several equities analysts recently commented on MESO shares. Maxim Group upgraded Mesoblast from a “hold” rating to a “buy” rating and set a $12.00 target price for the company in a research report on Tuesday, September 24th. Cantor Fitzgerald reissued an “overweight” rating on shares of Mesoblast in a report on Thursday, August 29th. Jefferies Financial Group raised shares of Mesoblast from a “hold” rating to a “buy” rating in a report on Thursday, August 29th. Finally, StockNews.com downgraded shares of Mesoblast from a “hold” rating to a “sell” rating in a report on Wednesday, September 4th. One equities research analyst has rated the stock with a sell rating and four have given a buy rating to the company’s stock. Based on data from MarketBeat, Mesoblast currently has a consensus rating of “Moderate Buy” and an average price target of $11.50.

Mesoblast Stock Up 3.9 %

The company has a debt-to-equity ratio of 0.21, a current ratio of 1.18 and a quick ratio of 1.18. The company has a 50-day simple moving average of $9.95 and a 200-day simple moving average of $8.00.

Institutional Trading of Mesoblast

Several hedge funds have recently modified their holdings of MESO. GAMMA Investing LLC raised its stake in shares of Mesoblast by 50.1% during the second quarter. GAMMA Investing LLC now owns 4,981 shares of the company’s stock worth $34,000 after buying an additional 1,663 shares during the last quarter. Chapin Davis Inc. grew its holdings in Mesoblast by 50.0% during the 2nd quarter. Chapin Davis Inc. now owns 15,000 shares of the company’s stock worth $102,000 after acquiring an additional 5,000 shares during the period. Pine Valley Investments Ltd Liability Co bought a new stake in shares of Mesoblast during the 2nd quarter valued at $80,000. Rathbones Group PLC acquired a new position in shares of Mesoblast in the 2nd quarter valued at $95,000. Finally, XTX Topco Ltd bought a new position in shares of Mesoblast in the 2nd quarter worth $103,000. 1.43% of the stock is owned by institutional investors.

Mesoblast Company Profile

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.